The Healthcare Technology Report is pleased to announce The Top 25 Biotech Executives of 2024. This year's awardees and their companies have made vital contributions to innovative new drug development, from cell therapy and genomic analysis to vaccine development, cancer treatment, immune reprogramming, and beyond. Several award recipients have also secured substantial funding to pave the way for more medical breakthroughs that will improve the lives of millions of patients around the world.
The honorees include the likes of Chief Innovation Officer of Maravai Life Sciences, Dr. Kate Broderick, who has led global teams in the collaboration and development of vaccines for a wide range of infectious diseases, including HIV and COVID-19. There’s also CEO and Co-Founder Serge Saxonov, whose leadership at 10x Genomics has resulted in more than 4,600 instruments in top institutions across the world, and work that has been cited in more than 7,000 research publications. And at LifeLabs, Lawrence Mahan’s expertise as SVP of Business and Consumer Markets has helped deliver over 112 million lab tests per year to diagnose, treat, monitor, and prevent diseases for millions of Canadians.
Standing out among hundreds of nominees, these individuals share an unwavering commitment to enhancing healthcare, advancing medical research, and ultimately saving more lives. We invite you to join us in applauding the accomplishments of The Top 25 Biotech Executives of 2024.
1. Paul J. Diaz
Company: Myriad Genetics
Title: President and CEO
Paul J. Diaz is the President and Chief Executive Officer of Myriad Genetics, as well as a member of the company’s board of directors. As a leader in genetic testing and precision medicine, Myriad Genetics is dedicated to advancing health and well-being for all. Under Diaz’s leadership, they provide insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent diseases.
Before joining Myriad Genetics, Diaz spent many years in high-level positions within the healthcare industry. Most recently, he was a partner at Cressey & Company, a middle-market private equity firm with over 30 years of success investing in and growing high-quality healthcare businesses. Before that, he served as President, CEO, and Vice Chairman of Kindred Healthcare, Inc. — a Fortune 500 company and one of the largest healthcare providers in the country.
Diaz currently serves on the board of directors of DaVita, the board of trustees of Johns Hopkins Medicine, and the board of visitors of the Georgetown University Law Center. Paul earned a bachelor’s degree in finance and accounting from American University’s Kogod School of Business and a law degree from Georgetown University Law Center.
2. Serge Saxonov
Company: 10X Genomics
Title: Chief Executive Officer
In 2012, Serge Saxonov co-founded 10x Genomics — an American biotechnology company that designs and manufactures gene sequencing technology that is vital to scientific research. As the CEO, he defined 10x's vision and strategy, contributed to core inventions, and has led the company since its inception.
Under Saxonov’s leadership, 10x’s innovative single cell, spatial, and in situ technologies have enabled discoveries across oncology, immunology, neuroscience, and more. 10x has placed more than 4,600 instruments in top institutions across the world, filed more than 1,750 patents, and has been cited in more than 7,000 research publications.
Prior to founding 10x Genomics, Saxonov was Vice President of Applications at QuantaLife, where he built products and defined the company’s growth areas. Saxonov was also previously the first employee at 23andMe, where he served as Founding Architect and Director of R&D. There he defined the initial concept of the product, built out the core technology, and drove strategy and execution of R&D functions. Saxonov received a Ph.D. in biomedical informatics from Stanford University and an A.B. in applied mathematics from Harvard College.
3. AmirAli Talasaz
Company: Guardant Health
Title: Co-Founder and Co-CEO
AmirAli Talasaz, Ph.D., is the Co-Founder and Co-CEO of Guardant Health, a precision medicine company focused on helping patients at all stages of cancer live longer and healthier lives. They do this through the power of blood tests and the data they unlock — from informing better treatment in patients with advanced cancer to developing new ways of monitoring recurrence in cancer survivors, and screening to find cancer at its earliest and most treatable stage.
With more than 17 years of experience, Talasaz is an entrepreneur in the rare genomics and clinical diagnostics fields. Prior to co-founding Guardant Health, he was Senior Director of Diagnostics Research at Illumina where he led efforts for emerging clinical applications of next-generation genomic analysis. Before that, he founded Auriphex Biosciences, Inc. to focus on the purification and genetic analysis of circulating tumor cells for cancer management — technology that was acquired by Illumina in 2009.
He has a Ph.D and M.S. in electrical engineering, as well as an M.S. in management science from Stanford University. During his academic years, he led the Technology Development group at Stanford Genome Technology Center.
4. Ying Huang
Company: Legend Biotech
Title: Chief Executive Officer
Ying Huang currently serves as Chief Executive Officer of Legend Biotech, a global biotechnology company focused on developing, manufacturing, and commercializing life-saving therapies. As CEO, Huang supports the company’s mission to reimagine healthcare and deliver transformative treatments through cell therapy.
With nearly a decade of experience in research and development at major multinational pharmaceutical companies, as well as 12 years of experience as a biotechnology analyst on Wall Street, Huang has made countless contributions to the healthcare industry. His previous roles include Managing Director and Head of Biotech Equity Research at Bank of America Merrill Lynch, as well as related positions at Wachovia, Credit Suisse, Gleacher, Barclays, and BofA Securities, Inc. Before his Wall Street career, Huang was a Principal Scientist at Schering-Plough (now Merck & Co.) in the Department of Chemical Research.
Huang is currently a member of the board of directors for Legend, as well as Quanta Therapeutics, and has co-authored multiple patents and peer-reviewed publications. He received his Ph.D. in bioorganic chemistry from Columbia University, and also studied at Columbia Business School, and in the Special Class for the Gifted Young at the University of Science and Technology of China.
5. Barry Greene
Company: Sage Therapeutics
Title: Chief Executive Officer
Barry Greene is the CEO of Sage Therapeutics. With more than 30 years of biopharmaceutical industry experience, Greene has been a member of the Sage Board of Directors since 2020. Under his leadership, he supports the biopharmaceutical company in its commitment to develop novel therapies with the potential to transform the lives of people with debilitating disorders of the brain.
Prior to Sage, Greene spent 17 years at Alnylam Pharmaceuticals, Inc., where he served as CEO before eventually advancing to President. Greene’s other leadership positions across the healthcare industry include General Manager of Oncology at Millennium Pharmaceuticals; Executive Vice President and Chief Business Officer for Mediconsult.com; and other related positions at AstraZeneca (formerly AstraMerck), and Andersen Consulting.
Greene is currently a member of the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA). He received his Bachelor of Science in Industrial Engineering from the University of Pittsburgh and served as a Senior Scholar at Duke University’s Fuqua School of Business.
6. Julie Rubinstein
Company: Adaptive Biotechnologies
Title: President, Chief Operating Officer
Julie Rubinstein is the President and Chief Operating Officer of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Since 2011, she has served in a variety of leadership roles at the company and currently oversees its Life Sciences Research, Clinical Diagnostics, Drug Discovery, Corporate Marketing, and Business Development functions. Rubinstein was also part of the executive team that took the company public in 2019.
Rubinstein has held various worldwide commercial development roles at Pfizer Oncology, primarily focusing on cancer immunotherapy. She has also held multiple positions at Johnson & Johnson’s Ethicon Endo-Surgery division, where she helped commercialize a breast cancer diagnostic device in major European markets. Before her now 30 years of experience, Rubinstein began her career in Morgan Stanley’s Global Health Care Group as a financial analyst.
Rubinstein currently serves on the board of trustees for The Valerie Fund, a pediatric oncology organization in New Jersey and New York. She has a Bachelor of Science in engineering and international management, and a Bachelor of Arts in communications from the University of Pennsylvania, as well as an MBA from Harvard Business School.
7. Jane Chung
Company: Sutro Biopharma
Title: President and Chief Operating Officer
Jane Chung, R.Ph., serves as Sutro Biopharma’s President and Chief Operating Officer, and previously served as Chief Commercial Officer. As CEO, she supports the company in transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need. To date, Sutro’s platform has led to antibody-drug conjugates (ADCs), bispecific antibodies, cytokine-based immuno-oncology therapies, and vaccines directed at precedented targets in clinical indications where the current standard of care is suboptimal.
With over 20 years of experience, Chung has held many leadership roles within the pharmaceutical and biotechnology sectors. Her experience includes President and General Manager of AstraZeneca Canada, as well as Vice President of Sales and Marketing of U.S. lmmuno-Oncology, and Senior Commercial Business Director. Before AstraZeneca, Chung served as a Regional Sales Director and Director of Sales Productivity and Effectiveness for Onyx Pharmaceuticals, Inc. Leading up to this, she assumed roles at Genentech, Inc. as Senior Marketing Manager, Division Manager, and Commercial Operations Manager.
Chung currently serves on the board of directors of Viracta Therapeutics, Inc., and on many nonprofit boards in the science, education, and community development arenas. Chung received a Bachelor of Arts from Columbia University and a Bachelor of Science in pharmacy from St. John’s University, New York.
8. Kate Broderick
Company: Maravai Life Sciences
Title: Chief Innovation Officer
As the Chief Innovation Officer of Maravai Life Sciences, Kate Broderick supports the Science and Innovation Office of a leading life sciences company dedicated to researching human diseases and providing critical products to enable the development of novel vaccines, drug therapies, and diagnostics.
With more than 20 years of life science experience and 15 years in research and development, Dr. Broderick is a recognized expert in vaccine and nucleic acid technology. She has led global teams and collaborated with industry, academic, and government partners to develop vaccines for a wide range of infectious diseases, including Ebola, MERS, Zika, HIV, Lassa fever, and COVID-19.
Before joining Maravai, Dr. Broderick held multiple roles of increasing responsibility at Inovio Pharmaceuticals, most recently as Senior Vice President of R&D. Dr. Broderick received her Ph.D. from the University of Glasgow in Scotland and completed post-doctoral research at the University of California, San Diego.
9. Mark J. Foley
Company: Revance
Title: President and CEO
Mark J. Foley is the CEO of Revance Therapeutics, where he has served as a member of the company’s board of directors since September 2017. Under his leadership, Revance is committed to setting a new standard in healthcare through innovative products that elevate both patient and physician experiences.
Foley has over 25 years of experience in the healthcare industry, having served in a variety of senior operating roles in both large public companies and venture-backed startups. Previously, he was Chairman, President, and CEO of ZELTIQ Aesthetics where he led a growth of $68 million in annual revenue to over $350 million. This led to an appreciation of stock and a $2.5 billion acquisition by Allergan. Before this, he held roles at the likes of RWI Ventures, the U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott), and Ventrica (acquired by Medtronic).
Foley currently co-chairs the Aesthetics Innovation Summit and serves on the board of directors for Glaukos Corp., an ophthalmic medical technology and pharmaceutical company. He received his bachelor’s degree from the University of Notre Dame and is named as an inventor on 17 patent applications.
10. Eric Shaff
Company: Seres Therapeutics
Title: President and CEO
As President and Chief Executive Officer of Seres Therapeutics, Eric Shaff leads a company founded on the belief that microbiome therapies can transform how diseases are treated. Through the combination of proprietary science, innovative technology, and rigorous analysis, Eric and his teams are striving to create a future of new treatment options that allow patients to thrive from the inside out.
Shaff has more than 20 years of experience working in executive leadership roles in biotechnology finance, corporate development, and capital markets. Prior to Seres, he was Vice President of Corporate Finance at Momenta Pharmaceuticals, where he helped manage accounting, finance, planning, and procurement, as well as investor relations efforts. Before joining Momenta, Shaff was Vice President of Finance at Genzyme’s Rare Genetic Disease Division, where he was responsible for a global portfolio of products with an annual revenue greater than $2 billion. Additionally, Shaff worked in corporate finance at Pfizer, and in investment banking for Broadview International (now Jefferies, LLC).
Eric holds a Bachelor of Arts in political science and economics from the University of Pennsylvania, and an MBA with a concentration in finance from the Johnson Graduate School of Management at Cornell University.
11. Scott Hutton
Company: Biodesix
Title: President, CEO, and Director
Scott Hutton is the President, CEO, and Director of Biodesix. Under his leadership, Biodesix has grown into a leading diagnostics company with a mission to unite biopharma companies, physicians, and patients to transform the standard of care and improve outcomes through personalized diagnostics. In October 2020, Hutton led the Biodesix team through the company’s IPO.
With 25+ years of experience in the diagnostic and medical device industries, Hutton has a proven track record leading high-performance teams — including those with 50+ product launches, strong brand reputations, and those who have improved the lives of tens of millions of patients globally. He joined Biodesix from Spectranetics, now part of Royal Philips, where he served until acquisition as Senior Vice President and General Manager of the Vascular Intervention division. Before joining Spectranetics, Hutton spent 16+ years at Medtronic where he most recently led the market share-leading neurosurgery business unit as Vice President and General Manager.
Hutton currently serves on the board of directors for the Coalition for 21st Century Medicine (C21), as well as on the Purdue University Public Health External Advisory Board, and the Eximis Surgical Board of Directors. Scott is a Purdue University alumnus, having earned a Bachelor of Arts degree from the College of Health and Human Sciences, Department of Health and Kinesiology.
12. J. Scotch McClure
Company: Maxwell Biosciences
Title: CEO, Co-Founder, Chairman of the Board
Scotch McClure is the CEO, Chairman, and Co-Founder of Maxwell Biosciences in Austin, TX, where he leads a team dedicated to the company’s vision: to create health for the world, safely and affordably. Founded in 2016 by McClure, Maxwell is a preclinical-stage biotechnology company developing a new class of broad-spectrum anti-infective therapeutics that attack the structure of most pathogens. Maxwell’s compounds target viruses, bacteria, fungi, and biofilm formations, including those that cause many currently untreatable infectious diseases.
Under McClure’s leadership, Maxwell has grown from a startup to a company raising a Series A round ahead of FDA clinical trials and expanding governmental and corporate partnerships. Maxwell aims to redefine global health by altering how we combat infectious diseases.
McClure is an engineer with over 20 years of experience as a CEO, and 10 years of experience as a Corporate Board Director. He is a multi-patent inventor, including antiviral applications of Maxwell’s platform and human gene expression technology. His background includes leading engineering and scientific research teams, as well as military intelligence and commercial applications such as high-tech hardware and software. From 1992 to 2001, he served with distinction in the United States Air Force, in highly classified financial, electronic, and other intelligence project management roles at the Electronic System Center and the Air Intelligence Agency. He holds a Bachelor of Science in management from the USAF Academy and an MBA from the University of Massachusetts.
13. Philina Lee
Company: Blueprint Medicines
Title: Chief Commercial Officer
Since April 2022, Lee has served as Chief Commercial Officer of Blueprint Medicines. She originally joined the team in 2014 as Senior Director of New Product Strategy and Development and subsequently held multiple commercial roles with responsibility for strategy, operations, patient services, marketing, and the precision medicine field team. During her tenure, she has built the company's portfolio up from the research stage and onward, laying the groundwork for the commercial strategy that is driving the successful launches of AYVAKIT® (avapritinib) and GAVRETO® (pralsetinib).
Philina Lee has more than 15 years of biopharmaceutical industry leadership experience, with a strong track record of product commercialization and building high-growth organizations while fostering a strong company culture. Previously, she served as Senior Vice President and Head of Portfolio Strategy and Program Management, where she was responsible for providing strategic and operational leadership across the company's portfolio. Lee has also held product strategy and marketing roles of increasing responsibility at Algeta, Sanofi, and Genzyme.
She currently serves on the Board of Fusion Pharmaceuticals, as a member of both the Nomination and Governance Committee and Research and Development Committee. Lee earned a Bachelor of Science in biochemistry from the University of Alberta, and a Ph.D. in cell biology from the Massachusetts Institute of Technology.
14. Cindy Dunkle
Company: Denali Therapeutics
Title: Chief People Officer
Cindy Dunkle serves as Chief People Officer at Denali Therapeutics, where she oversees all aspects of human resources, facilities, and environmental health and safety. Dunkle has been instrumental in growing the company from inception, positioning science and leadership as a focus for attracting and developing top talent.
With over 30 years of experience, Dunkle’s emphasis on compensation, organizational growth, development, and talent acquisition is vital to Denali’s mission to solve the challenges associated with neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and ALS.
Dunkle currently serves on the board of directors at Seek Labs; as vice chairman of the Board at BioHive Utah; and is a board manager at Life Science Cares Bay Area. Dunkle graduated from Metropolitan State University of Denver with an undergraduate degree in psychology.
15. Lawrence Mahan
Company: LifeLabs
Title: Senior Vice President, Business & Consumer Markets
As Senior Vice President of Business & Consumer Markets, Lawrence Mahan is responsible for driving revenue and profitability within LifeLabs’ B2B and B2C portfolio. His leadership and expertise supports LifeLabs in performing over 112 million laboratory tests per year to help diagnose, treat, monitor, and prevent diseases for millions of Canadians.
Mahan has extensive experience in the healthcare industry, having worked in European and North American markets in both the medical device and healthcare services sectors. Before joining LifeLabs, Mahan led the diagnostic system business at Becton Dickinson Canada, where his teams were recognized with global achievement awards on three separate occasions. He has also held several commercial leadership roles throughout his career, including biotechnology trading for the Czechoslovakian trading agency, Chemapol (UK), and business development throughout Western Europe for CellPro Inc. — a pioneer of stem cell-based therapy.
Mahan holds a Bachelor of Science in biochemistry from University College Cardiff and is a board member of the Inscyte Corporation, a not-for-profit health data technology company.
16. Angela Nelson
Company: Axogen
Title: VP, Regulatory Affairs
Angela Nelson serves as Axogen’s Vice President of Regulatory Affairs, where she leads the strategic direction for the company’s global regulatory strategy, including their transition to the first biological-designated product.
Nelson has more than 20 years of combined experience in business and regulatory strategy, program and project management and development, application of computational chemistry methodologies, and academia. Her professional background includes an executive appointment with PPD, an industry-leading clinical research organization, as well as Cardinal Health, where she executed multiple consultative and scientific product and strategy development positions for novel products. During her time with PPD, she oversaw the global regulatory science function of more than 100 regulatory professionals in 50 countries and was accountable for delivering regulatory and business-critical initiatives across all aspects and phases of the drug development and commercial processes.
Nelson previously held an academic faculty position at the University of Missouri-Kansas City’s School of Medicine, and currently holds an active global Regulatory Affairs Certification — the leading credential for regulatory professionals in the healthcare sector from the Regulatory Affairs Professional Society (RAPS). She has an MBA and Bachelor of Science in chemistry and psychology.
17. Michelle Chen
Company: Insilico Medicine
Title: Chief Business Officer
Michelle Chen, Ph.D., is the Chief Business Officer at Insilico Medicine, a leader in the AI-powered drug discovery and development field. She leads the company’s strategic, corporate, and global business development, thus supporting their mission to leverage their rapidly evolving, proprietary Pharma.AI platform across biology, chemistry, and clinical development.
As a biotech executive for more than 20 years, Chen has experience across various biopharma and technology companies. She was the former SVP and head of Corporate Development and Discovery Business Development at WuXi Biologics. Prior to that, she served as Executive Director of Business Development, Search and Evaluation at Merck, and held a biotechnology executive role at Roche. Chen has also previously worked at BioMarin, Agilent, and many other small biotech companies where she fostered her track record of success in company building, M&A, BD&L, investment, marketing, and R&D.
Michelle has a Ph.D. in biochemistry from the University of Washington, completed her postdoctoral work at UCSF, and received Bioinformatics training at Stanford.
18. Karen Massey
Company: Argenx
Title: Chief Operating Officer
Karen Massey is the COO of Argenx, a global immunology company committed to improving the lives of people living with severe autoimmune diseases. In her leadership role, she plays an important part in Argenx’s antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate the discovery of novel targets, disease pathways, and differentiated therapeutic antibodies.
Massey has over 20 years of experience in the pharmaceutical and biotechnology industry with a breadth of experience across commercial product development, and corporate strategy and innovation. Before joining Argenx, Massey was SVP of Product Development & Global Clinical Operations at Genentech. Prior to that, she had management and consulting roles at Bain and Company, and previously worked with Pfizer as a Senior Marketing Manager.
Massey graduated from NYU Stern School of Business with an MBA, and from the University of Sydney with an undergraduate degree in economics.
19. Dawn Hill
Company: BridgeBio
Title: Chief Clinical Operation Officer
Dawn Hill is the Chief Clinical Operation Officer of BridgeBio, a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients. The BridgeBio approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early-stage science into medicines that treat disease at its source. She originally joined the company as Vice President of Clinical Operations.
Hill has more than 25 years of experience in clinical trial management, outsourcing, and business development. Before joining BridgeBio, she spent seven years as Executive Director of Clinical Operations at OncoMed Pharmaceutics where she provided strategic oversight of multiple early-phase oncology trials across nine different compounds. Prior to OncoMed, she spent 14 years at a global full-service CRO, Omnicare/Clinimetrics, as Vice President of Business Operations where she was responsible for U.S. business development, project delivery, and contract management. Earlier in her career, She worked in clinical development at Chiron and Syntex Research.
Hill has a Bachelor of Science in biochemistry from the University of California at Davis.
20. Isabel Kalofonos
Company: ImmunoGen
Title: Chief Commercial Officer
As Chief Commercial Officer of ImmunoGen, Isabel Kalofonos supports a leading company in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, ImmunoGen aims to disrupt the progression of cancer and offer patients more good days.
Kalofonos has 21 years of experience in leadership roles. Before joining ImmunoGen, she served as Head of the Prescription Business unit at Galderma, where she led the launch preparation for nemolizumab, a monoclonal antibody for the treatment of atopic dermatitis and prurigo nodularis. She also oversaw the expansion of global market access, real-world evidence, pricing, and health economics and outcomes research. Before Galderma, she led Takeda Pharmaceuticals (formerly Shire) as Vice President and Head of the Hereditary Angioedema (HAE) franchise – a $2.5 billion business. In this role, she oversaw the global blockbuster launch of TAKHZYRO® (lanadelumab-flyo). Before Shire, she worked in commercial, business strategy, and product launch positions at Forest Labs, Bionevia Pharmaceuticals, and Sunovion Pharmaceuticals.
Kalofonos graduated from Babson College with an MBA in entrepreneurship and marketing, and from Pontificia Universidad Javeriana with an undergraduate degree in industrial engineering.
21. Timothy Miller
Company: Forge Biologics
Title: Co-Founder, President, and CEO
Timothy Miller is the Co-Founder, President, and CEO of Forge Biologics, a VC-backed gene therapy development engine focused on accelerating access to potentially life-saving AAV gene therapies. Under his leadership, Forge partners with innovators in the gene therapy community to help champion teams that are navigating the long road from the lab bench to the bedside.
With over 26 years of experience, Miller is a proven biotech leader with experience driving gene therapy pipeline development, regulatory strategy, investor relations, M&A activities, in-licensing, GMP manufacturing, clinical development, and leading stakeholder/shareholder engagement. Miller began his career as a scientist at Copernicus Therapeutics. From there, he went on to Juventas Therapeutics, Inc., before eventually rising to President and Chief Scientific Officer at Abeona Therapeutics, Inc.
Miller graduated from Case Western Reserve University with a Ph.D in pharmacology and molecular biology. He also has an undergraduate degree in biology/molecular biology from John Carroll University.
22. Rowena Albanna
Company: Aditxt Therapeutics
Title: Chief Operating Officer
Rowena Albanna is the COO of Aditxt Therapeutics, where she first began her tenure as an operations consultant. Rising in the ranks to COO, Albanna now plays a key leadership role in the company’s development of technologies focused on improving the health of the immune system through immune monitoring and reprogramming.
With over 20 years of experience serving in senior leadership roles, Albanna has a proven track record of fostering synergies between operational and technical proficiencies for both technology startups and public companies. This has led to expertise across a wide variety of industries including biotechnology, insect control, nanotechnology, consumer electronics, financial, telecommunications, e-commerce, online marketing, medical, and defense.
Previously, Albanna was COO at ieCrowd; a Principal at Weezies; and a Research Engineer at General Dynamics. Albanna earned an undergraduate degree in computer science from California State University-San Bernardino.
23. Nathalie Dubois-Stringfellow
Company: Sangamo Therapeutics
Title: Chief Development Officer
Nathalie Dubois-Stringfellow, Ph.D., serves as the Senior Vice President and Chief Development Officer of Sangamo Therapeutics. In her role, she oversees the development and execution of project team strategy for Sangamo’s zinc finger protein (ZFP) therapeutic programs in hemophilia, lysosomal storage disorders, hemoglobinopathies, HIV, and Huntington’s disease.
Dr. Dubois-Stringfellow has over 20 years of experience implementing and managing preclinical and clinical development of biologic therapies in oncology, as well as immune, infectious, and genetic diseases. Originally joining Sangamo in January 2011 as Senior Director of Project Management, she advanced at the company to become Senior Vice President of Product Development and Management before rising to her current role. Prior to this, she held various positions in discovery research, preclinical research, project management, clinical development, and portfolio management at Chiron Corp., Bayer Corp., Signature Biosciences, Inc., and most recently XOMA, LLC where she served as Senior Director of Preclinical Portfolio and Alliance Management.
Dr. Dubois-Stringfellow was a post-doctoral fellow at the University of North Carolina, Chapel Hill, where she studied angiogenesis and tumorigenesis in transgenic mice and cell culture systems. She received her M.S. in genetics and immunology and her Ph.D. in human genetics from the Université Pierre et Marie Curie in Paris, France.
24. Adrienne Farid
Company: Century Therapeutics
Title: Chief Operating Officer
Adrienne Farid is COO and Head of Early Development at Century Therapeutics, an innovative biotechnology company. Under Farid’s operations leadership, Century is building an industry-leading allogeneic iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development, and manufacturing capabilities to generate allogeneic, iPSC-derived NK and T-cell therapies for cancer and autoimmune and inflammatory diseases.
Before joining Century, Farid was Corporate Vice President of Project Leadership and Business Operations in Research & Early Development at Celgene. There, her group ran early development teams, was responsible for numerous IND and CTA filings, and progressed Phase 1/2 assets in hematology, oncology, and inflammation/immunology. Farid was co-lead of the initial global Liso-cel development team with Juno Therapeutics, and as part of collaboration governance, she was instrumental in contributing to Celgene’s cell therapy strategies. Earlier, Farid led global development teams, including Pomalyst® in relapsed/refractory multiple myeloma, through registration. At Roche for 15 years, she advanced through technical and global development leadership. Originally, she began her career at SmithKline Beecham.
Farid received her Ph.D in chemistry from Columbia University and completed post-doctoral studies at California Institute of Technology.
25. Laurie Minott
Company: BioTissue
Title: Chief People Officer
As Chief People Officer at BioTissue, Laurie Minott plays a key role in supporting a team that is pioneering the clinical application of human placental tissues. Founded in 1997, BioTissue is a leader in innovative technologies using products derived from human amniotic and umbilical cord tissues.
With more than 25 years of experience in human resources, Laurie was previously a partner with Great Place to Work®, a global management consultancy that produces the FORTUNE 100 Best Companies to Work For® list. Laurie served as a senior strategic advisor to the CEO, CHRO, and executive teams of global clients in areas including HR strategy, executive and team coaching, design and implementation of large-scale change, and organizational and leadership development. Her clients included Brooks Brothers, Four Seasons Hotel & Resorts, Wegmans Food Markets, St. Jude Children’s Research Hospital, Roche Diagnostics, and others.
Laurie holds a Bachelor of Science in business administration from Husson University and a Master of Science in Organizational Development from Case Western Reserve University.
